Citations (20)
Keep up to date with the latest research on this topic with citation updates for this article.
Read on this site (1)
Thomas Decker Christensen, Erik Lerkevang Grove, Peter Brønnum Nielsen & Torben Bjerregaard Larsen. (2016) Self-managed oral anticoagulant therapy: a call for implementation. Expert Review of Cardiovascular Therapy 14:3, pages 255-257.
Read now
Read now
Articles from other publishers (19)
S. R. Gilyarevsky, N. K. Vereina & M. V. Golshmid. (2023) Current insights into the possible role of laboratory monitoring of effectiveness and safety of direct oral anticoagulants. Rational Pharmacotherapy in Cardiology 19:3, pages 290-297.
Crossref
Crossref
Robert C. Gosselin, Emmanuel J. Favaloro & Jonathan Douxfils. (2022) The myths behind DOAC measurement: Analyses of prescribing information from different regulatory bodies and a call for harmonization. Journal of Thrombosis and Haemostasis 20:11, pages 2494-2506.
Crossref
Crossref
Jia‐Wei Ng, Nor Asyikin Mohd Tahir, Paul Ken Leong Chin, Mohd Makmor‐Bakry & Shamin Mohd Saffian. (2022) A systematic review and meta‐analysis of dabigatran peak and trough concentration in adults. British Journal of Clinical Pharmacology 88:10, pages 4443-4459.
Crossref
Crossref
Jonathan Douxfils, Dorothy M. Adcock, Shannon M. Bates, Emmanuel J. Favaloro, Isabelle Gouin-Thibault, Cecilia Guillermo, Yohko Kawai, Edelgard Lindhoff-Last, Steve Kitchen & Robert C. Gosselin. (2021) 2021 Update of the International Council for Standardization in Haematology Recommendations for Laboratory Measurement of Direct Oral Anticoagulants. Thrombosis and Haemostasis 121:08, pages 1008-1020.
Crossref
Crossref
Adela-Nicoleta Roşian, Mihaela Iancu, Adrian Pavel Trifa, Ştefan Horia Roşian, Cristina Mada, Cornelia Paula Gocan, Teodora Niţă, Sabina Istratoaie, Paul-Mihai Boarescu & Anca Dana Buzoianu. (2020) An Exploratory Association Analysis of ABCB1 rs1045642 and ABCB1 rs4148738 with Non-Major Bleeding Risk in Atrial Fibrillation Patients Treated with Dabigatran or Apixaban. Journal of Personalized Medicine 10:3, pages 133.
Crossref
Crossref
Suman M. Wasan, Natalie Feland, Russell Grant & Christopher E. Aston. (2019) Validation of apixaban anti-factor Xa assay and impact of body weight. Thrombosis Research 182, pages 51-55.
Crossref
Crossref
Juan Pablo Salazar Adum, Iva Golemi, Luis H. Paz, Luis Diaz Quintero, Alfonso J. Tafur & Joseph A. Caprini. (2018) Venous thromboembolism controversies. Disease-a-Month 64:9, pages 408-444.
Crossref
Crossref
J. Douxfils, W. Ageno, C.‐M. Samama, S. Lessire, H. ten Cate, P. Verhamme, J. ‐M. Dogné & F. Mullier. (2018) Laboratory testing in patients treated with direct oral anticoagulants: a practical guide for clinicians. Journal of Thrombosis and Haemostasis 16:2, pages 209-219.
Crossref
Crossref
E. Chaussade, Olivier Hanon, C. Boully, F. Labourée, L. Caillard, G. Gerotziafas, J.-S. Vidal & I. Elalamy. (2018) Real-Life Peak and Trough Dabigatran Plasma Measurements Over Time in Hospitalized Geriatric Patients with Atrial Fibrillation. The journal of nutrition, health & aging 22:1, pages 165-173.
Crossref
Crossref
Virginie Dubois, Anne-Sophie Dincq, Jonathan Douxfils, Brigitte Ickx, Charles-Marc Samama, Jean-Michel Dogné, Maximilien Gourdin, Bernard Chatelain, François Mullier & Sarah Lessire. (2017) Perioperative management of patients on direct oral anticoagulants. Thrombosis Journal 15:1.
Crossref
Crossref
W.C.Y. Lau, X. Li, I.C.K. Wong, K.K.C. Man, G.Y.H. Lip, W.K. Leung, C.W. Siu & E.W. Chan. (2017) Bleeding‐related hospital admissions and 30‐day readmissions in patients with non‐valvular atrial fibrillation treated with dabigatran versus warfarin. Journal of Thrombosis and Haemostasis 15:10, pages 1923-1933.
Crossref
Crossref
Anne-Laure Sennesael, Thomas Exner, Bernard Chatelain, Sarah Lessire, Anne-Sophie Larock, Christelle Vancraeynest, Lionel Pochet, Jean-Michel Dogn?Anne Spinewine, Fran?ois Mullier & Jonathan Douxfils. (2017) An optimized dRVVT-based assay to estimate the intensity of anticoagulation in patients treated with direct oral anticoagulants. Thrombosis Research 157, pages 29-37.
Crossref
Crossref
Lina Sabor, Mélanie Raphaël, Jean-Michel Dogné, François Mullier & Jonathan Douxfils. (2017) Heparin-calibrated chromogenic anti-Xa assays are not suitable to assess the presence of significant direct factor Xa inhibitors levels. Thrombosis Research 156, pages 36-38.
Crossref
Crossref
I. Gouin‐Thibault, X. Delavenne, A. Blanchard, V. Siguret, J.E. Salem, C. Narjoz, P. Gaussem, P. Beaune, C. Funck‐Brentano, M. Azizi, P. Mismetti & M.A. Loriot. (2017) Interindividual variability in dabigatran and rivaroxaban exposure: contribution of ABCB1 genetic polymorphisms and interaction with clarithromycin. Journal of Thrombosis and Haemostasis 15:2, pages 273-283.
Crossref
Crossref
Xuanmiao Zhang, Mei Hu, Guangfei Wei, Mengdi Jia, Tao Gong & Ji Liu. (2017)
An injectable
in situ
lipid phase transition system for sustained delivery of dabigatran etexilate with low burst release
. RSC Advances 7:89, pages 56594-56601.
Crossref
Crossref
Luigi Brunetti, Betty Sanchez-Catanese, Leonid Kagan, Xia Wen, Min Liu, Brian Buckley, James P. Luyendyk & Lauren M. Aleksunes. (2016) Evaluation of the chromogenic anti-factor IIa assay to assess dabigatran exposure in geriatric patients with atrial fibrillation in an outpatient setting. Thrombosis Journal 14:1.
Crossref
Crossref
Jonathan Douxfils, Lionel Pochet, Sarah Lessire, Christelle Vancraeynest, Jean-Michel Dogné & François Mullier. (2016) Mass spectrometry in the therapeutic drug monitoring of direct oral anticoagulants. Useful or useless?. TrAC Trends in Analytical Chemistry 84, pages 41-50.
Crossref
Crossref
Ovidiu Vornicu, Anne-Sophie Larock, Jonathan Douxfils, François Mullier, Virginie Dubois, Maximilien Gourdin, Sarah Lessire & Anne-Sophie Dincq. (2016) Minimisation of Bleeding Risks Due to Direct Oral Anticoagulants. EMJ Hematology, pages 78-90.
Crossref
Crossref
J. Douxfils, B. Chatelain, C. Chatelain, J.-M. Dogné & F. Mullier. (2015) Edoxaban: Impact on routine and specific coagulation assays. Thrombosis and Haemostasis 115:2, pages 368-381.
Crossref
Crossref